NCT00006243View on ClinicalTrials.gov

Vaccine Therapy and Sargramostim in Treating Patients With Stage IV Malignant Melanoma

NACompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 31, 2000

Primary Completion Date

May 31, 2006

Conditions
Recurrent MelanomaStage IV Melanoma
Interventions
BIOLOGICAL

tyrosinase peptide

Given SC

BIOLOGICAL

MART-1:27-35 peptide vaccine

Given SC

BIOLOGICAL

gp100 antigen

Given SC

BIOLOGICAL

incomplete Freund's adjuvant

Given SC

BIOLOGICAL

sargramostim

Given SC

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

55905

Mayo Clinic, Rochester

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00006243 - Vaccine Therapy and Sargramostim in Treating Patients With Stage IV Malignant Melanoma | Biotech Hunter | Biotech Hunter